Trial Profile
Beta 3 Agonist Treatment in Heart Failure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms Beat-HF
- 18 Dec 2016 Primary endpoint of increase in LVEF (measured by MRI or CT) has not been met, according to results published in the European Journal of Heart Failure.
- 18 Dec 2016 Results published in the European Journal of Heart Failure
- 02 Mar 2016 Status changed from recruiting to completed, as reported by European Clinical Trials Database.